阿德木單抗
化合物
阿德木單抗（INN：Adecatumumab；開發代號：MT201）是一種重組人IgG1單株抗體，用於靶向腫瘤細胞。它與上皮細胞黏附分子 (EpCAM - CD326) 結合，旨在觸發抗體依賴性細胞毒性。它是由Micromet Inc開發的，該公司被安進收購。[1]
| 單株抗體 | |
|---|---|
| 種類 | 完整抗體 |
| 目標 | EpCAM |
| 臨床資料 | |
| ATC碼 |
|
| 識別資訊 | |
| CAS號 | 503605-66-1  |
| ChemSpider |
|
| UNII | |
| 化學資訊 | |
| 化學式 | C6552H10080N1740O2052S46 |
| 摩爾質量 | 147,533.60 g·mol−1 |
參考資料
- ^ Adecatumumab - Amgen/Merck Serono. Adis Insight. Springer Nature Switzerland AG. [2024-01-22]. （原始內容存檔於2017-11-03）.
- ^ Oberneder R, Weckermann D, Ebner B, Quadt C, Kirchinger P, Raum T, et al. A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. European Journal of Cancer. October 2006, 42 (15): 2530–8. PMID 16930989. doi:10.1016/j.ejca.2006.05.029.
- ^ Prang N, Preithner S, Brischwein K, Göster P, Wöppel A, Müller J, et al. Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. British Journal of Cancer. January 2005, 92 (2): 342–9. PMC 2361858
. PMID 15655555. doi:10.1038/sj.bjc.6602310.
- ^ Schmidt M, Scheulen ME, Dittrich C, Obrist P, Marschner N, Dirix L, et al. An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Annals of Oncology. February 2010, 21 (2): 275–82. PMID 19633042. doi:10.1093/annonc/mdp314 .
